Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
‘Faster together’: AstraZeneca breaks into clinical services business with new company launch, lining up two CRO partners to start
LONDON — AstraZeneca has launched a new global health tech business, Evinova, after seeing a gap in the market to reduce the time and cost
November 21, 2023